staflor

[staflor @vikloic]

“If you are that special lover (woo)
And love keeps you tied to another
That's the way it goes on love's train
You don't need no, you don't need no ticket to ride “

[Dr Rishabh Jain @DrRishabhOnco]

🌸 THE 10 MOST IMPORTANT BREAST CANCER TRIALS OF #ASCO26

Chicago is loaded this year.

From ctDNA-guided endocrine switching to frontline ADCs and next-gen HER2 platforms, these are the studies most likely to shape breast oncology practice 👇

🩷 HR+ / HER2- DISEASE

1️⃣ persevERA BC (LBA1006)
Giredestrant + palbociclib vs letrozole + palbociclib in 1L metastatic disease

Despite missing the primary PFS endpoint, biomarker/subset analyses may define where oral SERDs still fit.

2️⃣ SERENA-6 (LBA1007)
Camizestrant for emergent ESR1 mutations detected via ctDNA BEFORE radiographic progression

Possibly the biggest ctDNA-guided endocrine strategy discussion of the meeting.

3️⃣ VIKTORIA-1
Gedatolisib + fulvestrant ± palbociclib after AI + CDK4/6i progression

Huge unmet-need population.
Post-CDK4/6 sequencing remains one of the biggest HR+ questions.

4️⃣ lidERA BC (Abstract 502)
Adjuvant giredestrant in early ER+/HER2- disease

Moving oral SERDs into curative-intent therapy.

5️⃣ FOURLIGHT-2 (Abstract 1042)
Next-gen CDK4-selective inhibition with atirmociclib + letrozole

Can we reduce neutropenia while preserving efficacy?

🔥 TNBC & ADC ERA

6️⃣ ASCENT-04 (LBA1000)
Sacituzumab govitecan + pembrolizumab vs chemo + pembrolizumab in PD-L1+ mTNBC

Could ADC + IO combinations become the frontline standard?

7️⃣ TROPION-Breast02
Dato-DXd vs chemotherapy in metastatic TNBC

A major test of the “ADC-first” paradigm.

🎯 HER2+ & NEXT-GEN NEOADJUVANT PLATFORMS

8️⃣ KN026-004 (LBA660)
Novel biparatopic HER2 antibody vs classic CLEOPATRA-style therapy

Watch the pCR data carefully.

9️⃣ I-SPY 2.2 (LBA514)
Rilvegostomig + T-DXd in high-risk HER2-negative disease

IO + ADC combinations continue moving earlier.

🔟 DESTINY-Breast05 Update
Long-term outcomes for T-DXd vs T-DM1 in residual HER2+ disease

Which breast abstract are you watching most closely?

#BCSM #OncoTwitter #ASCO26 #BreastCancer #MedEd @asco @myesmo @esmo_open @OncoAlert @OncBrothers

[Dr Rupam Manna MD @DrRupamOncology]

🚨 HYPOKALEMIA IN ONCOLOGY – The sneaky but deadly electrolyte emergency every oncologist must master!
Hypokalemia is extremely common in cancer patients and can cause muscle weakness, paralysis, QT prolongation → Torsades, arrhythmias, and sudden death — while also amplifying chemotherapy toxicity.
This high-yield infographic covers everything:
✅ Major causes in oncology (GI losses from chemo, cisplatin-induced renal wasting, drug-induced, hypomagnesemia, ectopic ACTH, cancer cachexia)
✅ ECG progression (flattened T waves → prominent U waves → QT prolongation → VT/VF)
✅ When it becomes an emergency + practical evaluation
✅ Step-by-step management (treat cause + safe K replacement + magnesium correction is NON-NEGOTIABLE)
Key Clinical Pearls 🔥
• Hypomagnesemia makes hypokalemia refractory — always correct Mg simultaneously or K replacement fails!
• Never give IV potassium as a push/bolus — dangerous!
• KCl is the preferred salt in most oncology patients
• Platinum agents (especially cisplatin) are one of the biggest culprits
Save this for your next ward round or night call 📌
Perfect companion to the Hyperkalemia in Oncology infographic!
RT to help fellows & residents 🔥
Follow @DrRupamOncology for more high-yield Cancer Concepts Explained
#Hypokalemia #Oncology #MedTwitter #MedEd #FOAMed #Electrolytes #CancerCare #Chemotherapy #TumorLysis #FOAMed

[Dr Rupam Manna MD @DrRupamOncology]

🚨 Why Must Gemcitabine Be Administered Over 30 Minutes?
Gemcitabine is traditionally infused over 30 minutes because longer infusion times (>60 min) significantly increase toxicity — especially myelosuppression, fatigue & constitutional symptoms — without clearly improving efficacy in standard practice.
This high-yield infographic breaks down: ✅ Pharmacologic basis (prodrug → dCK activation → dFdCDP & dFdCTP) ✅ Why 30 minutes is optimal (best efficacy–toxicity balance) ✅ What happens with prolonged or Fixed Dose Rate (FDR) infusion ✅ PK concept (AUC & intracellular exposure) ✅ Common regimens & practical clinical pearl
🔖 Save this as your quick reference
📌 Share with your residents, fellows, chemo unit & oncology team!
Cancer Concepts Explained by
Dr Rupam Manna MD
Medical Oncologist
@DrRupamOncology
#Gemcitabine #Chemotherapy #Oncology #MedEd #OncoTwitter #MedTwitter #CancerEducation #CancerConceptsExplained

[staflor @vikloic]

@Rconstantino Nossa, imagina quando você souber das roubalheiras e artimanhas do PT. Btw, você ouviu falar sobre a mudança da coordenação dos inquéritos relacionados às fraudes no Instituto Nacional de Seguro Social (INSS) só pra livrar a cara do Lulinha? Se sim, pode mudar de foco por favor?

[Dr Rupam Manna MD @DrRupamOncology]

🚨 Jaundice in a cancer patient is an oncologic emergency until proven otherwise.

From malignant biliary obstruction to immune-mediated hepatitis, rapid diagnosis and timely intervention can be lifesaving.

📌 Key focus:
✅ Obstructive vs hepatocellular vs hemolytic jaundice
✅ Cholangitis recognition
✅ ERCP/PTBD decision-making
✅ Immunotherapy hepatitis management
✅ Chemotherapy dose considerations
✅ Practical oncology algorithm for real-world practice

Early biliary decompression and sepsis control often determine outcomes.

#Oncology #MedicalOncology #Jaundice #Cholangitis #LiverMetastasis #Immunotherapy #CancerCare #ERCP #Hepatology #GIOncology #PancreaticCancer #Cholangiocarcinoma #CancerEducation #MedEd #FOAMed #DrRupamManna

[Dr Rishabh Jain @DrRishabhOnco]

🚨 FDA expands the role of Enhertu in curative-intent HER2+ early breast cancer.

AstraZeneca + Daiichi Sankyo’s trastuzumab deruxtecan is now approved in the US in BOTH:
🔹 Neoadjuvant setting (DESTINY-Breast11)
🔹 Adjuvant residual disease setting (DESTINY-Breast05)

Key data 👇

🔹 DESTINY-Breast11
Enhertu → THP vs ddAC-THP
📈 pCR:
67.3% vs 56.3%
Absolute improvement: +11.2% (p=0.003)

🔹 DESTINY-Breast05
Enhertu vs T-DM1 in residual disease
📉 IDFS events reduced by 53%
(HR 0.47)

📊 3-year IDFS:
92.4% vs 83.7%

This potentially reshapes BOTH pre-op and post-op HER2+ early breast cancer management.

But important caution:
⚠️ ILD/pneumonitis remains clinically relevant.
In DESTINY-Breast05:
• ILD: 9.6% with Enhertu
• 2 treatment-related deaths reported

Still, this is a major move of T-DXd deeper into curative-intent disease.

📖 Full details:
AstraZeneca press release

#BreastCancer #OncoTwitter #MedTwitter @OncoAlert @myesmo @esmo_open @asco

[Entisar saleh @Entisar_kilani]

Brain tumors in flash !

#oncology #oncoflash #medtwitter

[Santiago Oquendo MD @rksanti]

💉🩺 DEXAMETASONA EN URGENCIAS
Glucocorticoide potente y de acción prolongada con efecto:
✅ Antiinflamatorio
✅ Antiedema
✅ Antialérgico
✅ Inmunosupresor
⚙️ Mecanismo de acción:
🔹 Inhibe mediadores inflamatorios (prostaglandinas y citocinas)
🔹 Disminuye permeabilidad capilar y edema
🔹 Reduce respuesta inmune exagerada
🔹 Disminuye inflamación de vía aérea

📌 Usos frecuentes en urgencias:
🚑 Crup
🚑 Asma y sibilancias
🚑 Anafilaxia (adyuvante)
🚑 Edema cerebral NO traumático
🚑 Meningitis bacteriana
🚑 Antiemético
💡 Perlas clínicas:
🔹 La vía oral suele ser tan efectiva como IV/IM en cuadros leves-moderados.
🔹 La ampolla IV puede administrarse VO en pediatría.
🔹 NO reemplaza adrenalina en anafilaxia.
🔹 Su larga vida media permite muchas veces dosis única.
📚 Medicina práctica y basada en urgencias.
#Dexametasona #Urgencias #Pediatría #Asma #Crup #Emergencias #Farmacologia #DrSoquendo #EducacionMedica

[Dr Rupam Manna MD @DrRupamOncology]

📊 NAPOLI-1 Trial Summary | Nanoliposomal Irinotecan in Metastatic Pancreatic Cancer

The landmark Phase III study that changed second-line therapy forever.

✅ Median OS: 6.1 vs 4.2 months
✅ HR 0.67 (p=0.012)
✅ Now standard of care (NCCN & international guidelines) after gemcitabine failure

Full visual breakdown with trial design, toxicities, mechanism & clinical pearl 👇

#PancreaticCancer #GIOnc #Oncology #MedTwitter #CancerResearch

Follow for more Cancer Concepts Explained 👉 @DrRupamOncology

[Dr Rupam Manna MD @DrRupamOncology]

Rituximab – Side Effects & Administration Guide 🧬
One of the most commonly used monoclonal antibodies in lymphoma, CLL, autoimmune diseases & vasculitis.
This high-yield infographic covers everything you need:
✅ Premedication & baseline evaluation
✅ Safe infusion rates (first vs subsequent)
✅ Infusion-related reactions (highest risk in 1st cycle)
✅ Tumor Lysis Syndrome precautions
✅ Mandatory Hepatitis B screening & reactivation risk
✅ PML, hematologic, cardiac, pulmonary toxicities
✅ Practical oncology pearls & reaction management
Essential quick reference for residents, fellows, hem-onc teams & nurses!
🔖 Save this post
📌 Share with your team
Cancer Concepts Explained by
Dr Rupam Manna
Medical Oncologist
@DrRupamOncology
#Rituximab #Lymphoma #CLL #HemOnc #Oncology #MedTwitter #MedEd #CancerEducation

[Dr Rishabh Jain @DrRishabhOnco]

🚨 AstraZeneca update in bladder cancer.

Phase III VOLGA trial met its primary endpoint:
Perioperative durvalumab (Imfinzi) + neoadjuvant enfortumab vedotin (EV) significantly improved EFS in cisplatin-ineligible or cisplatin-declining MIBC. 🔥

🧪 Trial arms:
1️⃣ Durvalumab + EV + tremelimumab
2️⃣ Durvalumab + EV
🆚
🏥 Radical cystectomy ± adjuvant therapy

📌 Key takeaways:
✅ Statistically significant & clinically meaningful EFS benefit
✅ Favorable OS trend
✅ Manageable safety profile
✅ Potential perioperative option for cisplatin-unfit patients

After NIAGARA and POTOMAC, VOLGA becomes another major positive perioperative bladder cancer readout for durvalumab.

The perioperative uro-oncology landscape is changing rapidly.

📖 Full release in comment ⬇️

#BladderCancer #uroonc #MedTwitter @OncoAlert @myesmo @esmo_open @asco @AstraZe

[Dr Rupam Manna MD @DrRupamOncology]

🔬 Significance of Serum Free Light Chain (SFLC) in Multiple Myeloma
My latest comprehensive infographic on this key biomarker that has transformed diagnosis, prognosis, renal monitoring & treatment decisions in MM.
Covers everything in one visual: ✅ Basic concept & what SFLC actually measures
✅ Normal ranges + κ/λ ratio
✅ IMWG myeloma-defining event (involved/uninvolved SFLC ratio ≥100)
✅ Light-chain, oligosecretory & non-secretory myeloma + AL amyloidosis
✅ Risk stratification & prognostic implications
✅ Myeloma cast nephropathy & renal failure
✅ Rapid treatment monitoring (half-life 2–6 hrs!)
✅ Early relapse detection & practical clinical pearls
Save 📌 this as your quick reference guide!
Cancer Concepts Explained by Dr Rupam Manna
Follow for more → @DrRupamOncology
#MultipleMyeloma #SFLC #Myeloma #Oncology #HemOnc #MedEd #MedTwitter #Hematology

[Entisar saleh @Entisar_kilani]

Gastric cancer in flash thread .

#oncology #oncoflash #medtwitter

[Dr Rupam Manna MD @DrRupamOncology]

🌸 Metastatic Esophageal Cancer – Complete Management Blueprint
Your one-stop visual guide for real-world practice!
Covers:
• Goals of care & biomarker testing (HER2, PD-L1, MSI)
• First-line strategies for HER2+ / HER2– adenocarcinoma & squamous cell carcinoma
• Immunotherapy + chemo combinations (KEYNOTE-811, 590, CheckMate 648/649)
• Second-line options, T-DXd, ramucirumab, supportive care & palliative pearls
• Simplified practical algorithm + landmark trials
Essential for medical oncologists, fellows, hem-onc nurses & tumor boards managing advanced esophageal cancer.
Save 🔖 | Share with your team | Use daily in clinic
What’s your preferred 1L regimen for PD-L1 CPS ≥10 adenocarcinoma? Drop it below 👇
#EsophagealCancer #Oncology #MedTwitter #CancerCare #FOAMed #Immunotherapy #GICancer
Follow @DrRupamOncology for more “Cancer Concepts Explained” visuals!

[Dr Rupam Manna MD @DrRupamOncology]

🛡️ CINV Management – ASCO / NCCN / MASCC-ESMO Guideline-Based Practical Summary
CINV remains one of the most distressing toxicities of cancer therapy…
But modern prophylaxis prevents nausea/vomiting in >80–90% patients when guideline-based antiemetics are used properly.
This infographic gives you everything in one place:
• Types of CINV (Acute, Delayed, Anticipatory, Breakthrough, Refractory)
• Emetogenic risk stratification (HEC/MEC/Low/Minimal)
• Preferred 4-drug regimen for Highly Emetogenic Chemo (incl. AC)
• Breakthrough & anticipatory CINV management
• Quick reference algorithm + clinical pearls
Perfect quick reference for daily oncology practice!
Save this infographic 👇
Share with your residents, fellows & team
#CINV #Oncology #MedicalOncology #Chemotherapy #ASCO #NCCN #ESMO #MedTwitter #CancerCare
Cancer Concepts Explained 🌸
Follow @DrRupamOncology for more such practical tools

[Dr Rupam Manna MD @DrRupamOncology]

🧠 Triple IT (Triple Intrathecal Therapy) is a cornerstone of CNS prophylaxis and treatment in hematologic malignancies.

Understanding the role of:
✔️ Methotrexate
✔️ Cytarabine
✔️ Hydrocortisone

is essential in managing:
🔹 ALL
🔹 High-grade lymphomas
🔹 CNS leukemia/lymphoma
🔹 Leptomeningeal disease

⚠️ And remember:
Intrathecal Vincristine = FATAL neurotoxicity.

A must-know concept for every oncology trainee and clinician.

#TripleIT #IntrathecalTherapy #MedicalOncology #HemOnc #ALL #Lymphoma #CNSLeukemia #LeptomeningealDisease #Chemotherapy #OncologyEducation #MedEd #CancerConcepts #DrRupamManna #OncologyResident #Hematology #NeuroOncology #CancerConceptsExplained

[Dr Rupam Manna MD @DrRupamOncology]

🧠 LEPTOMENINGEAL METASTASIS (LM) / LEPTOMENINGEAL CARCINOMATOSIS – High-Yield Overview
LM is one of the most devastating complications of advanced cancer. Tumor cells spread to the leptomeninges + CSF, causing multifocal neurologic deficits involving the brain, cranial nerves, and spine simultaneously — a classic clinical clue!
This infographic covers: ✅ What is LM & the leptomeninges
✅ Pathophysiology & why incidence is rising
✅ Most common cancers (Breast, Lung — esp. EGFR/ALK/SCLC, Melanoma)
✅ Clinical features (cerebral, cranial nerve, spinal)
✅ Diagnosis (MRI “sugar-coating”, CSF analysis, advanced testing)
✅ Prognosis
✅ Goals of treatment & major modalities (Systemic therapy, Intrathecal, Radiation, Supportive care, Ommaya reservoir)
✅ Emerging concepts & practical pearls
Essential reading for every oncology trainee, fellow & practicing oncologist!
#LeptomeningealMetastasis #LM #NeuroOncology #CancerConceptsExplained #OncologyEducation #MedicalOncology
Follow for more high-yield visuals → @DrRupamOncology

[Dr Rupam Manna MD @DrRupamOncology]

🔬 HOW DOXORUBICIN CAUSES CARDIOTOXICITY ❤️

Anthracyclines remain among the most powerful anticancer drugs — but cardiotoxicity is their major dose-limiting toxicity.

⚠️ Key mechanisms:
• ROS & free radical injury
• Iron-mediated oxidative damage
• Topoisomerase IIβ inhibition
• Mitochondrial dysfunction
• Cardiomyocyte apoptosis

📌 Important pearls:
✅ Dose-dependent & cumulative toxicity
✅ CHF risk rises sharply after 400–550 mg/m²
✅ Dexrazoxane is the specific cardioprotective agent
✅ Anthracycline toxicity is often irreversible unlike HER2 therapy-related dysfunction

🩺 Monitoring:
• Echocardiography & GLS
• Troponin / BNP
• Early detection is critical

#Oncology #CardioOncology #Doxorubicin #Anthracycline #MedicalOncology #CancerEducation #Chemotherapy #Cardiotoxicity #HeartFailure #OncoCardiology #HematologyOncology #MedEd #FOAMed #DrRupamManna #CancerConceptsExplaine

[Dr Rishabh Jain @DrRishabhOnco]

A new RAS era in pancreatic cancer?

Daraxonrasib, an oral RAS(ON) multiselective inhibitor, showed activity in previously treated RAS-mutated PDAC.

🧬 Phase 1-2 | N=168
💊 Oral daily daraxonrasib
🎯 2L RAS G12, 300 mg: ORR 35%
📈 mPFS 8.5 mo | mOS 13.1 mo
⚠️ Grade ≥3 TRAEs: 30%

Key nuance: single-arm early-phase study. Phase 3 RASolute 302 will define its real place.

📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #PancreaticCancer #GIOnc @OncoAlert @myESMO @NEJM